http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2523844-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f11390a0601d6520c1d8695c6a4f6744
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4833
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-6429
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-96
classificationIPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L2-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-96
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-04
filingDate 2005-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_411dfa9c7aec99babd66dc22dc027b93
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46723d17c00a6f0f5c87db7e4d6800e4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc410014b9529d3658f9e6a0022d1b5c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9a313ab33ee9864d70193078ee41df4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73009061ff98449a206bf8a21e498649
publicationDate 2006-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CA-2523844-A1
titleOfInvention Stable thrombin composition
abstract The stable thrombin composition comprises purified thrombin, human albumin and a neutral salt, the resulting product being stable when stored as a lyophilisate or frozen and is adjusted to a nominal strength of 500 IU of thrombin or more per ml of solution, the human albumin being in a concentration of over 0.05% (w/v) and preferably between 0.1% (w/v) and 1% (w/v).
priorityDate 2004-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425553238
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID750
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID90470996
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID409206349
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6224
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453213080
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448670727
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID431577138
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419537453
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5284359
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP84122
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID517045
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5234

Total number of triples: 41.